FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W34784395> ?p ?o ?g. }

• W34784395 endingPage "368" @default.
• W34784395 startingPage "357" @default.
• W34784395 abstract "The aim of this study was to describe the process to obtain Food and Drug Administration (FDA) approval for the expanded indication for treatment with the Resolute zotarolimus-eluting stent (R-ZES) (Medtronic, Inc., Santa Rosa, California) in patients with coronary artery disease and diabetes.The R-ZES is the first drug-eluting stent specifically indicated in the United States for percutaneous coronary intervention in patients with diabetes.We pooled patient-level data for 5,130 patients from the RESOLUTE Global Clinical Program. A performance goal prospectively determined in conjunction with the FDA was established as a rate of target vessel failure at 12 months of 14.5%. In addition to the FDA pre-specified cohort of less complex patients with diabetes (n = 878), we evaluated outcomes of the R-ZES in all 1,535 patients with diabetes compared with all 3,595 patients without diabetes at 2 years.The 12-month rate of target vessel failure in the pre-specified diabetic cohort was 7.8% (upper 95% confidence interval: 9.51%), significantly lower than the performance goal of 14.5% (p < 0.001). After 2 years, the cumulative incidence of target lesion failure in patients with noninsulin-treated diabetes was comparable to that of patients without diabetes (8.0% vs. 7.1%). The higher risk insulin-treated population demonstrated a significantly higher target lesion failure rate (13.7%). In the whole population, including complex patients, rates of stent thrombosis were not significantly different between patients with and without diabetes (1.2% vs. 0.8%).The R-ZES is safe and effective in patients with diabetes. Long-term clinical data of patients with noninsulin-treated diabetes are equivalent to patients without diabetes. Patients with insulin-treated diabetes remain a higher risk subset. (The Medtronic RESOLUTE Clinical Trial; NCT00248079; Randomized, Two-arm, Non-inferiority Study Comparing Endeavor-Resolute Stent With Abbot Xience-V Stent [RESOLUTE-AC]; NCT00617084; The Medtronic RESOLUTE US Clinical Trial (R-US); NCT00726453; RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population [R-Int]; NCT00752128; RESOLUTE Japan-The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent [RJ]; NCT00927940)." @default.
• W34784395 created "2016-06-24" @default.
• W34784395 creator A5003964745 @default.
• W34784395 creator A5008596377 @default.
• W34784395 creator A5021162166 @default.
• W34784395 creator A5026598797 @default.
• W34784395 creator A5030031948 @default.
• W34784395 creator A5041084808 @default.
• W34784395 creator A5053194091 @default.
• W34784395 creator A5057128973 @default.
• W34784395 creator A5072857168 @default.
• W34784395 creator A5076880659 @default.
• W34784395 creator A5081743465 @default.
• W34784395 creator A5083493788 @default.
• W34784395 creator A5089531887 @default.
• W34784395 date "2013-04-01" @default.
• W34784395 modified "2023-10-18" @default.
• W34784395 title "Clinical Outcome of Patients With and Without Diabetes Mellitus After Percutaneous Coronary Intervention With the Resolute Zotarolimus-Eluting Stent" @default.
• W34784395 cites W105018345 @default.
• W34784395 cites W120407998 @default.
• W34784395 cites W1946152282 @default.
• W34784395 cites W1964365699 @default.
• W34784395 cites W1976425217 @default.
• W34784395 cites W1993019255 @default.
• W34784395 cites W2001880655 @default.
• W34784395 cites W2005571796 @default.
• W34784395 cites W2005690811 @default.
• W34784395 cites W2022856209 @default.
• W34784395 cites W2024851355 @default.
• W34784395 cites W202580452 @default.
• W34784395 cites W2043797566 @default.
• W34784395 cites W2052893559 @default.
• W34784395 cites W2065255191 @default.
• W34784395 cites W2072289636 @default.
• W34784395 cites W2076148221 @default.
• W34784395 cites W2087150869 @default.
• W34784395 cites W2093743872 @default.
• W34784395 cites W2096237432 @default.
• W34784395 cites W2096409056 @default.
• W34784395 cites W2112494872 @default.
• W34784395 cites W2133452492 @default.
• W34784395 cites W2133525542 @default.
• W34784395 cites W2134293572 @default.
• W34784395 cites W2141196495 @default.
• W34784395 cites W2141834634 @default.
• W34784395 cites W2144552468 @default.
• W34784395 cites W2145999403 @default.
• W34784395 cites W2147673265 @default.
• W34784395 cites W2150086052 @default.
• W34784395 cites W2153314625 @default.
• W34784395 cites W2157647947 @default.
• W34784395 cites W2210189158 @default.
• W34784395 cites W2219391852 @default.
• W34784395 cites W2232858378 @default.
• W34784395 cites W2316681362 @default.
• W34784395 cites W2615022822 @default.
• W34784395 cites W38055810 @default.
• W34784395 cites W8997607 @default.
• W34784395 cites W95957117 @default.
• W34784395 doi "https://doi.org/10.1016/j.jcin.2012.11.006" @default.
• W34784395 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23523454" @default.
• W34784395 hasPublicationYear "2013" @default.
• W34784395 type Work @default.
• W34784395 sameAs 34784395 @default.
• W34784395 citedByCount "83" @default.
• W34784395 countsByYear W347843952013 @default.
• W34784395 countsByYear W347843952014 @default.
• W34784395 countsByYear W347843952015 @default.
• W34784395 countsByYear W347843952016 @default.
• W34784395 countsByYear W347843952017 @default.
• W34784395 countsByYear W347843952018 @default.
• W34784395 countsByYear W347843952019 @default.
• W34784395 countsByYear W347843952020 @default.
• W34784395 countsByYear W347843952021 @default.
• W34784395 countsByYear W347843952022 @default.
• W34784395 countsByYear W347843952023 @default.
• W34784395 crossrefType "journal-article" @default.
• W34784395 hasAuthorship W34784395A5003964745 @default.
• W34784395 hasAuthorship W34784395A5008596377 @default.
• W34784395 hasAuthorship W34784395A5021162166 @default.
• W34784395 hasAuthorship W34784395A5026598797 @default.
• W34784395 hasAuthorship W34784395A5030031948 @default.
• W34784395 hasAuthorship W34784395A5041084808 @default.
• W34784395 hasAuthorship W34784395A5053194091 @default.
• W34784395 hasAuthorship W34784395A5057128973 @default.
• W34784395 hasAuthorship W34784395A5072857168 @default.
• W34784395 hasAuthorship W34784395A5076880659 @default.
• W34784395 hasAuthorship W34784395A5081743465 @default.
• W34784395 hasAuthorship W34784395A5083493788 @default.
• W34784395 hasAuthorship W34784395A5089531887 @default.
• W34784395 hasBestOaLocation W347843951 @default.
• W34784395 hasConcept C126322002 @default.
• W34784395 hasConcept C134018914 @default.
• W34784395 hasConcept C141071460 @default.
• W34784395 hasConcept C164705383 @default.
• W34784395 hasConcept C2777546689 @default.
• W34784395 hasConcept C2778213512 @default.
• W34784395 hasConcept C2778583881 @default.

• next